Literature DB >> 12944097

Drug discovery in the ubiquitin regulatory pathway.

Brian R Wong1, Francesco Parlati, Kunbin Qu, Susan Demo, Todd Pray, Jianing Huang, Donald G Payan, Mark K Bennett.   

Abstract

The ubiquitin system has been implicated in the pathogenesis of numerous disease states, including oncogenesis, inflammation, viral infection, CNS disorders and metabolic dysfunction. Ubiquitin conjugation and deconjugation to substrate proteins is carried out by multiple families of proteins, each with a defined role in the enzymatic cascade. This conjugation-deconjugation system parallels the kinase-phosphatase system in that both alter protein function by the addition and removal of post-translational modifiers. Our understanding of ubiquitin biology and strategies to interfere pharmacologically with the ubiquitin regulatory machinery is progressing rapidly. In light of increased interest in ubiquitin pathways as drug targets, we review the ubiquitin enzymatic cascades, highlighting therapeutic opportunities and enzymatic mechanisms. We also discuss the challenges of targeting this class of enzymes with small molecules, as well as current approaches and progress in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944097     DOI: 10.1016/s1359-6446(03)02780-6

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  18 in total

1.  Human proteome-scale structural modeling of E2-E3 interactions exploiting interface motifs.

Authors:  Gozde Kar; Ozlem Keskin; Ruth Nussinov; Attila Gursoy
Journal:  J Proteome Res       Date:  2012-01-10       Impact factor: 4.466

Review 2.  New and emerging pharmacological targets for neuropathic pain.

Authors:  Donald C Manning
Journal:  Curr Pain Headache Rep       Date:  2004-06

3.  Small ubiquitin-like modifying protein isopeptidase assay based on poliovirus RNA polymerase activity.

Authors:  Jamie J Arnold; Alejandro Bernal; Uzo Uche; David E Sterner; Tauseef R Butt; Craig E Cameron; Michael R Mattern
Journal:  Anal Biochem       Date:  2005-11-17       Impact factor: 3.365

Review 4.  Deubiquitinating enzymes as novel anticancer targets.

Authors:  Benjamin Nicholson; Jeffrey G Marblestone; Tauseef R Butt; Michael R Mattern
Journal:  Future Oncol       Date:  2007-04       Impact factor: 3.404

5.  Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A.

Authors:  Yan Shi; Larry R Solomon; Ana Pereda-Lopez; Vincent L Giranda; Yan Luo; Eric F Johnson; Alexander R Shoemaker; Joel Leverson; Xuesong Liu
Journal:  J Biol Chem       Date:  2011-09-02       Impact factor: 5.157

6.  Immunoproteasome in the blood plasma of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.

Authors:  E Matuszczak; A Sankiewicz; W Debek; E Gorodkiewicz; R Milewski; A Hermanowicz
Journal:  Clin Exp Immunol       Date:  2017-10-16       Impact factor: 4.330

Review 7.  Regulation of translesion DNA synthesis: Posttranslational modification of lysine residues in key proteins.

Authors:  Justyna McIntyre; Roger Woodgate
Journal:  DNA Repair (Amst)       Date:  2015-02-18

Review 8.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

9.  Regulation of USP28 deubiquitinating activity by SUMO conjugation.

Authors:  Yang Zhen; Philip A Knobel; Travis H Stracker; David Reverter
Journal:  J Biol Chem       Date:  2014-10-30       Impact factor: 5.157

Review 10.  In silico pharmacology for drug discovery: applications to targets and beyond.

Authors:  S Ekins; J Mestres; B Testa
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.